Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 20Glioblastoma 12Neoplasms 10Breast Neoplasms 10Pancreatic Neoplasms 9Glioma 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Fallopian Tube Neoplasms 4Carcinoma 4Astrocytoma 4Oligodendroglioma 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2

Interventions

poly ICLC 1Vinorelbine 1Therapeutics 1Probiotics 1Poly I-C 1Pemetrexed 1Paclitaxel 1Monatide (IMS 3015) 1Docetaxel 1Cosmetics 1Cisplatin 1Carboplatin 1Blood Specimen Collection 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinogenesis × poly ICLC × Clear all
NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡